Willkie Farr & Gallagher LLP represented SCVX in the transaction, while Latham & Watkins LLP and Wolf Theiss represented Bright Machines. SCVX (NYSE: SCVX), a special...
Bright Machines’ Merger with SCVX
Rain Therapeutics’ $125 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
Treace Medical Concepts’ $106.3 Million Initial Public Offering
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
Alkami Technology’s $180 Million Initial Public Offering
Latham & Watkins LLP represented Alkami in the offering, Davis Polk advised the representatives of the several underwriters. Alkami Technology, Inc., a leading cloud-based digital banking...
Reneo Pharmaceuticals’ $93.8 Million Initial Public Offering
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...
Design Therapeutics’s $276 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc. Design Therapeutics, Inc. executed its initial public...
Airbnb’s $2 Billion Convertible Senior Notes Offering
Latham & Watkins LLP represented Airbnb in the offering. Airbnb, Inc. executed its offering of US$2 billion aggregate principal amount of 0% convertible senior notes due...
Hippo’s Merger with Reinvent Technology Partners Z
Latham & Watkins LLP acted as Hippo’s legal counsel, while Sullivan & Cromwell LLP served as Reinvent’s legal counsel for the transaction. Davis Polk advised the...
Angion Biomedica’s Initial Public Offering and Concurrent Private Placement
Latham & Watkins LLP represented Angion in the offering and private placement. Angion Biomedica Corp. (NASDAQ:ANGN) has announced the pricing of its initial public offering of 5...